Full-Time

Commercial Strategy Leader

Hospital Patient Monitoring

Posted on 11/1/2025

Philips

Philips

Manufactures sleep therapy and respiratory devices

Compensation Overview

$145k - $290k/yr

+ Annual incentive bonus + Sales commission + Long-term incentives

No H1B Sponsorship

United States

In Person

Travel up to 25% of the time.

Category
Business & Strategy (3)
, ,
Required Skills
Sales
Marketing
Data Analysis
Requirements
  • 8+ years combined business development and strategy consulting experience from a credible international consulting firm or in a corporate strategy department of a large international corporation
  • minimum of 3 years’ experience in the medical technology, medical device, or medical services industry
  • You must be able to travel potentially 25% of the time
  • Bachelor’s degree, required or Master’s degree, strongly preferred in Business, Science, Healthcare Administration, a related field or equivalent
  • US work authorization is a precondition of employment
Responsibilities
  • Partner closely with Sales, Marketing, and Customer Success to ensure commercial strategies translate into field execution and measurable outcomes.
  • Defining and tracking KPIs to measure the impact of strategy on revenue growth, profitability, and market share
  • Engaging directly with key customers, IDNs, and hospital executives to validate strategy and strengthen partnerships.
  • Acting as a change leader to align internal teams on strategic priorities, ensuring communication and adoption across functions
  • Driving and facilitating strategic program development and execution for Philips North America’s HPM business.
  • Developing winning commercial strategies with the HPM leadership team in NA, including GTM strategies, channel strategies, strategic partnerships, investment planning, and M&A strategy and integration
  • Foster a culture of innovation within the organization, encouraging the development of new ideas and exploring opportunities for disruptive technologies and business models
  • Anticipate the potential impact of possible industry and regulatory changes on the company's strategy and recommend necessary adjustments
  • In collaboration with global strategy, marketing, and analytics functions, maintaining strategic awareness of key market conditions and dynamics, competition, voice of the customer, and innovation trends for the HPM domain in North America
  • Working in a matrixed organization with business units, global strategists, market analysis and forecasting teams, marketing intelligence, and R&D teams to unlock HPM growth in North America, ensuring execution of the strategy, including business case development, strategy deployment, financial and operational alignment
Desired Qualifications
  • Experience in software, SaaS, digital health, and informatics strongly preferred
  • Knowledge of US healthcare reimbursement models, value-based care initiatives, and their implications for patient monitoring, strongly preferred
  • Master’s degree strongly preferred in Business, Science, Healthcare Administration, a related field or equivalent
  • People leadership experience preferred

Philips Respironics designs sleep and respiratory care devices, including CPAP and BiPAP machines, ventilators, and oxygen concentrators, plus related systems. These devices deliver regulated air pressure, support or assist breathing, and provide concentrated oxygen, often paired with software and data tools for monitoring. The division differentiates itself through its long history within Philips and its integrated ecosystem that connects devices with analytics and clinical support across hospital, clinic, and home settings. Its goal is to improve quality of life and clinical outcomes for people with sleep and respiratory conditions by offering reliable devices, patient support, and data-driven care.

Company Size

N/A

Company Stage

Acquired

Total Funding

$5.1B

Headquarters

Murrysville, Pennsylvania

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • BioTelemetry acquisition in 2020 expands remote heart monitoring.
  • $479 million settlement in September 2023 closes US litigation.
  • New silicone foam validated safe, enabling global device sales.

What critics are saying

  • ResMed seizes US sleep market share within 6-12 months.
  • FDA consent decree blocks US sales until after 2026.
  • January 2024 US ventilation exit halves revenue permanently.

What makes Philips unique

  • Pioneered CPAP therapy as standard for sleep apnea since 1976.
  • Leads in non-invasive ventilation and home respiratory support.
  • Integrates devices with software for data-driven clinical outcomes.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Health Savings Account/Flexible Spending Account

Company News

HIT Consultant
Apr 12th, 2024
Philips Respironics Reaches Final Agreement With Us Regulators On Sleep Apnea Device Recall

<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US,  subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024.  The company’s previously announced 2023-2025 financial outlook remains unchanged,  already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more

Goodrich Pharmacy
Jan 29th, 2024
Phillips Suspends U.S. Sales of CPAP, Ventilator Machines After Recall

Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.

Parker Waichman LLP
Mar 23rd, 2023
Sleep Apnea Patients Suffer While Waiting To Receive Their Repaired Philips CPAP Machines

In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.

Digital Journal
Jan 13th, 2023
Ultrasound Market Share | Market | Report | Analysis 2032 | Key Players: Fujifilm Holdings Corporation, Analogic Corporation, Siemens Healthcare among others

February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.

VentureBeat
Oct 26th, 2022
Philips Norelco Brings Movember To Roblox With Shavetopia

Register now for your free virtual pass to the Low-Code/No-Code Summit this November 9. Hear from executives from Service Now, Credit Karma, Stitch Fix, Appian, and more. Learn more. Philips Norelco is creating an interactive metaverse experience called Shavetopia in Roblox, based around the Movember trend. For anyone who doesn’t know what that is, Movember is where people grow facial hair for the entire month of November. The portmanteau comes from adding the word mustache to the name of the month

INACTIVE